Department of Pathology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Virchows Arch. 2022 Aug;481(2):283-293. doi: 10.1007/s00428-022-03342-3. Epub 2022 Jun 3.
Plasmablastic myeloma (PBM) is a blastic morphologic variant of plasma cell myeloma with less favorable prognosis than those with non-blastic morphology. PBM is rare, without clear-cut definition and detailed clinicopathologic features in the literature. PBM may mimic plasmablastic lymphoma (PBL) as they share nearly identical morphology and immunophenotype. Using the criteria of ≥ 30% plasmablasts in tissue sections, we retrospectively recruited PBM cases and analyzed their clinical, imaging, and pathologic findings, with emphasis on extramedullary involvement. We performed immunohistochemistry, in situ hybridization for Epstein-Barr virus (EBER), and fluorescence in situ hybridization (FISH) for lymphoma- and myeloma-associated genetic alterations. Of the 25 recruited cases, 15 (60%) had extramedullary involvement, which occurred as initial presentation in nine cases. The most common extramedullary sites were soft tissue and/or skin (10/15, 67%), followed by pleural effusion, the lungs, and lymph nodes. Immunohistochemically, tumor cells expressed MYC (74%; 17/23), CD56 (56%; 14/25), and cyclin D1 (16%; 4/25), while CD117 was all negative (n = 25). Of the 20 cases stained with p53, four (20%) cases were diffusely positive, and the remaining 16 cases showed a heterogeneous pattern. EBER was negative in all 24 cases examined. Of the 13 cases examined with FISH, the genetic aberrations identified included del(13q14)(92%; 12/13), gain of chromosome 1q (90%; 9/10), loss of chromosome 1p (60%; 6/10), IGH-FGFR3 reciprocal translocation (23%; 3/13), rearranged MYC (15%; 2/13), and rearranged CCND1 (8%; 1/13), while there were no cases with TP53 deletion (n = 10) or rearrangement of BCL2 (n = 13) or BCL6 (n = 13). The prognosis was dismal regardless of the presence or absence of extramedullary involvement. In conclusion, PBM in Taiwan frequently presented as extramedullary and extranodal lesions, particularly in soft tissue and/or skin, mimicking PBL. FISH for targeted genetic alterations such as del(13q14), gain of chromosome 1q, loss of chromosome 1p, and IGH-FGFR3 might be helpful for the differential diagnoses. Larger studies are warranted to investigate the genetic alterations between PBM and PBL.
浆母细胞骨髓瘤(PBM)是浆细胞骨髓瘤的成母细胞形态变异型,其预后较非成母细胞形态差。PBM 较为罕见,文献中尚无明确的定义和详细的临床病理特征。PBM 可能与浆母细胞淋巴瘤(PBL)相混淆,因为它们具有几乎相同的形态和免疫表型。我们使用组织切片中≥30%浆母细胞的标准,回顾性地招募了 PBM 病例,并分析了他们的临床、影像学和病理发现,重点是髓外受累。我们进行了免疫组织化学、EB 病毒(EBER)原位杂交和淋巴瘤和骨髓瘤相关遗传改变的荧光原位杂交(FISH)。在 25 名被招募的病例中,有 15 名(60%)存在髓外受累,其中 9 名病例为首发表现。最常见的髓外受累部位是软组织和/或皮肤(10/15,67%),其次是胸腔积液、肺部和淋巴结。免疫组织化学染色显示,肿瘤细胞表达 MYC(74%;17/23)、CD56(56%;14/25)和 cyclin D1(16%;4/25),而 CD117 均为阴性(n=25)。在 20 例用 p53 染色的病例中,有 4 例(20%)弥漫阳性,其余 16 例呈异质性模式。所有 24 例检查的 EBER 均为阴性。在进行 FISH 检查的 13 例病例中,确定的遗传异常包括 del(13q14)(92%;12/13)、染色体 1q 获得(90%;9/10)、染色体 1p 缺失(60%;6/10)、IGH-FGFR3 相互易位(23%;3/13)、MYC 重排(15%;13/13)和 CCND1 重排(8%;1/13),而无 TP53 缺失(n=10)或 BCL2 重排(n=13)或 BCL6 重排(n=13)。无论是否存在髓外受累,预后均较差。总之,台湾的 PBM 常表现为髓外和结外病变,特别是在软组织和/或皮肤,类似于 PBL。针对 del(13q14)、染色体 1q 获得、染色体 1p 缺失和 IGH-FGFR3 等靶向遗传异常的 FISH 可能有助于鉴别诊断。需要更大规模的研究来探讨 PBM 和 PBL 之间的遗传改变。